Dr. Bernick has received research support from Haymon Boxing, Top Rank Promotions, and the Ultimate Fighting Championship. Dr. Geda has received funding from the Barrow Neurological Foundation, NIH (grant R01 AG057708), and Roche; and he has served on the advisory board of Lundbeck. Dr. Wethe is a cocreator of Mayo Clinic Concussion Check, which incorporates the King-Devick Test, in association with the Mayo Clinic. Dr. Katz has received royalties from Springer/Demos Publishing for a textbook on brain injury, he has served as an expert witness in legal cases involving brain injury and concussion, he has received a stipend from Encompass Health as program medical director for brain injury and chair of the annual Neurorehabilitation Conference, and he has received honoraria for a keynote address for the annual medical directors meeting of HealthSouth. Dr. Alosco has received research support from Life Molecular Imaging and the Rainwater Charitable Foundation, he has received a single-time honorarium from the Michael J. Fox Foundation, and he has received royalties from Oxford University Press. Dr. Tripodis has received financial support from the American Medical Association. Dr. Adler has served as a consultant for Avion, CND Life Sciences, Jazz, and PreCon Health. Dr. Balcer has served as editor-in-chief of the Journal of Neuro-Ophthalmology, and her spouse co-owns a patent on an N-methyl-d-aspartate receptor antibody assay. Dr. Reiman has been a compensated scientific adviser to Alkahest, Alzheon, Aural Analytics, Cognition Therapeutics Denali, Enigma, Green Valley, Retromer Therapeutics, and Vaxxinity; and he is a cofounder of, shareholder with, and adviser to ALZPath. Dr. Cummings has served as a consultant to Acadia, Actinogen, Acumen, AlphaCognition, Aprinoia, AriBio, Artery, Biogen, Biohaven, BioVie, Bristol-Myers Squib, Cassava, Cerecin, Diadem, EIP Pharma, Eisai, GAP Innovations, GemVax, Genentech, Janssen, Jocasta, Karuna, Lighthouse, Lilly, LSP/EQT, Lundbeck, Mangrove Therapeutics, Merck, NervGen, New Amsterdam, Novo Nordisk, Oligomerix, Ono, Optoceutics, Otsuka, Oxford Brain Diagnostics, PRODEO, Prothena, ReMYND, Roche, Sage Therapeutics, Signant Health, Simcere, Sinaptica, Suven, SynapseBio, TrueBinding, Vaxxinity, and Wren pharmaceutical, assessment, and investment companies; he has been supported by the Alzheimer’s Disease Drug Discovery Foundation, the Joy Chambers-Grundy Endowment, NIH (grants P20GM109025, U01NS093334, R01AG053798, P30AG072959, R35AG71476, R25AG083721), and the Ted and Maria Quirk Endowment; he owns the copyright of the Neuropsychiatric Inventory; and he is a shareholder with Acumen, Alzheon, Artery, Behrens, MedAvante-Prophase, and Vaxxinity. Dr. Stern has been a member of the Board of Directors of King-Devick Technologies, and he has received royalties for published neuropsychological tests from Psychological Assessment Resources. The other authors report no financial relationships with commercial interests.